Abstract. Liver fibrosis is one of the major liver pathologies affecting patients worldwide. It results from an improper tissue repair process following liver injury or inflammation. If left untreated, it ultimately leads to liver cirrhosis and liver failure. Long non-coding RNAs (lncRNAs) have been implicated in a wide variety of diseases. They can regulate gene expression and modulate signaling. Some of the lncRNAs promote, while others inhibit liver fibrosis. Similarly, other epigenetic processes, such as methylation and acetylation regulate gene transcription and can modulate gene expression. Notably, there are several regulatory associations of lncRNAs with other epigenetic processes. A major mechanism of action of long non-coding RNAs is to competitively bind to their target microRNAs (miRNAs or miRs), which in turn affects miRNA availability and bioactivity. In the present review, the role of lncRNAs and related epigenetic processes contributing to liver fibrosis is discussed. Finally, various potential therapeutic approaches targeting lncRNAs and related epigenetic processes, which are being considered as possible future treatment targets for liver fibrosis are identified.

1. Introduction

Hepatic fibrosis results from an aberrant wound healing process in the liver. In general, fibrosis results from an accumulation of extracellular matrix (ECM) proteins. Pathogenetically, apart from the abnormal deposition of ECM proteins, the improper degradation of ECM proteins also occurs (1,2). Liver fibrosis results from persistent wound repair and regenerative processes due to continued hepatic injury caused by chronic liver diseases, such as non-alcoholic steatohepatitis (NASH), the excessive consumption of alcohol, hepatitis B and C infection, obstruction in the bile ducts, etc. (3,4), ultimately leading to cirrhosis and predisposing affected patients towards the development of malignancies, such as hepatocellular carcinoma (HCC) (4-7). Although extensive research has been made into liver fibrosis (as discussed below), the mechanisms governing the process are not yet fully understood.

Hepatic stellate cells (HSCs), which are primarily involved in growth, regeneration and differentiation comprise 5-8% of total liver cells (8). The activation of HSCs is a key step in liver fibrosis, as it leads to the accumulation of the ECM proteins, α-smooth muscle actin (α-SMA) and type I collagen (9,10). Non-activated or quiescent HSCs lose their vitamin A stores and transdifferentiate into fibrogenic myofibroblast-like cells following liver injury (11-14). Therefore, the suppression of HSC activation is crucial for the therapy of liver fibrosis.

Transcriptome analysis, gene expression profiling by microarray and RNA sequencing have increasingly pointed to the role of non-coding RNAs (ncRNAs) as crucial regulators of gene expression and signal transduction (15). In liver carcinogenesis and fibrosis, ncRNAs have emerged as key regulators of gene expression (16-18). Therefore, ncRNAs may also be viewed as putative biomarkers for diagnosis and therapeutic targets for the treatment of liver fibrosis. Among the ncRNAs, major players include microRNAs (miRNAs or miRs) and long non-coding RNAs (lncRNAs). lncRNAs with sizes of ≥200 nucleotides, are categorized into 4 subgroups as follows: Exonic, intronic, intergenic and bidirectional, depending on their placement and orientation with respect to protein coding genes. In liver fibrosis, lncRNAs may act as...
competitive endogenous RNAs (ceRNA), sponging miRNAs. This action releases the inhibition imposed by miRNAs on mRNA translation, thereby indirectly regulating gene expression. Other members of the ncRNA group include circular RNAs, PIWI-interacting RNAs, etc. (19).

Epigenetics encompass the changes in gene expression, that do not involve mutations in the DNA sequence. Epigenetic alterations are long-lasting and are heritable. Epigenetic alterations bring about changes in DNA properties along with transcriptional regulation. The epigenetic regulation of genes is significant in terms of gene expression and physiological function. Furthermore, epigenetic alterations are key pathogenetic mechanisms involved in various, if not all chronic diseases (20) involving all organs, such as skeletal muscle (21), the brain (22), heart (23), ovaries (24) and bones (25).

Epigenetic regulators can turn ‘on or off’ the expression of genes, depending on the prevailing microenvironment. Along with ncRNAs, other epigenetic processes include DNA and histone methylations and other biochemical mechanisms, causing alterations of DNA and histones. Such processes control several biological processes, such as genome imprinting, transposon mediated gene silencing, X chromosome inactivation, etc. (26). DNA methylation is catalyzed by DNA methyltransferases (DNMT). There are 3 DNMTs, namely DNMT1, DNMT3a and DNMT3b. Histone methylation is carried out by a balancing act between histone methyltransferase and histone dimethyl transferase (26). Additional epigenetic histone modification involves the addition/removal of acetyl groups on histone proteins. Histone acetylation is carried out by a group of enzymes known as histone acetyl transferases (HATs) and deacetylation is carried by histone deacetylases (HDACs). These 2 enzymes play important regulatory roles in HSC activation and the development of liver fibrosis (27). Other less well-studied mechanisms include ubiquitination, NEDDylation and SUMOylation. The targeting of ubiquitin enzymes has been shown to improve the physiology in liver fibrosis (28). Transforming growth factor-β (TGF-β) is a cytokine secreted by the immune system. It has been demonstrated that the TGF-β signaling pathway plays a crucial role in the development and progression of liver fibrosis (29). The dynamic interactions of IncRNAs with various pathways, such as miRNAs, DNA, histone methylation and histone acetylation are illustrated in Fig. 1.

The present review focuses on the role of IncRNAs in the promotion and inhibition of liver fibrosis. Furthermore, the interaction of IncRNAs with signaling pathways and the regulation of liver fibrosis through DNA methylation and acetylation is explored. The present review also discusses possible therapeutic implications of such processes in the treatment of liver fibrosis.

2. Regulation of liver fibrosis by IncRNAs

The transcriptome profiling of quiescent and activated HSCs lead to a better understanding of the mechanistic roles of IncRNAs in the promotion or inhibition of liver fibrosis (30,31). A large volume of data have been obtained from the genome-wide screening of HSCs and tissues from human and animal models with respect to the expression patterns of IncRNAs. Understanding these expression patterns and their resulting regulation of cellular pathways are important for the development of targeted therapies for liver fibrosis. As will be evident from the discussions below, IncRNAs play diverse roles in mediating liver fibrosis. Some function as activators of liver fibrosis, whereas others may exert inhibitory effects. In addition, some of them may also play a dual role.

**IncRNAs as activators of liver fibrosis.** IncRNAs which activate liver fibrosis are usually upregulated or overexpressed in liver tissues affected by fibrosis. These IncRNAs activate HSCs and promote ECM protein overexpression. Several of these IncRNAs also activate the TGF-β signaling pathway. As they are all upregulated, a potential therapeutic approach under consideration is IncRNA blockade using a small molecule or siRNA. The discussions below focus on specific IncRNAs and their roles in such processes.

The IncRNA, nuclear paraspeckle assembly transcript-1 (NEAT-1), may act as a miRNA sequestering agent. In a recent study, it was found that NEAT-1 regulated the localization of miR-29b to the cytoplasm (32). Insulin like growth factor binding protein related protein 1 (IGFBPrP1) interacts with the TGF-β signaling pathway to promote liver fibrosis (33). IGFBPrP1 induces the activation and autophagy of HSCs, which is regulated by Atg9a and NEAT-1, while miR-29b inhibits such a process (31), indicating that the NEAT-1/Atg9a/miR-29b pathway regulates liver fibrosis. NEAT-1 overexpression and its downstream effects on liver fibrosis are further prevented by Kruppel like factor 6 (KLFL6) knockdown and miR122 overexpression (34). Therefore, NEAT-1/miR-122/KLFL6 may function as another regulatory mechanism for liver fibrosis, modulating multiple signaling pathways.

Hox transcript antisense RNA (HOTAIR) has been found to be overexpressed in carbon tetrachloride (CCL4)-induced liver fibrosis in human and mouse models (30). HOTAIR binds to miR-148b and regulates the DNMT1/MEG3/p53 pathway in HSCs (35). It has also been reported that the HOTAIR-mediated downregulation of miR-29b attenuates its epigenetic control, inducing the hypermethylation of the phosphatase and tensin homolog (PTEN) gene, resulting in the progression of liver fibrosis (36). It is of further interest to note that one miRNA; i.e, miR29b, may regulate multiple, seemingly unrelated IncRNAs, such as NEAT-1 and HOTAIR, leading to the development of hepatic fibrosis.

Hox A distal transcript (HOTTIP) is a IncRNA which promotes HSC activation and fibrosis by functioning as a competitive endogenous RNA (ceRNA) for miR-148a and miR-150, and inducing the expression of serum response factor (SRF) (37). High HOTTIP levels reduce the expression of miR-148a, removing its inhibitory effects and thus increasing levels of TGF-β receptor type 1 (TGFBR1) and receptor 2 (TGFBR2), thereby promoting liver fibrosis (38).

Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) expression has been found to be upregulated in liver fibrosis; MALAT1 regulates the expression of sirtuin 1 (SIRT1), which deacetylates Smad3, a mediator of the TGF-β signaling pathway and inhibits its binding to its target genes like collagen type 1 promoter (39). Through such an activation of SIRT1, the downregulation of the TGF-β signaling pathway and the inhibition of liver fibrosis may occur. MALAT1 also induces mouse HSC activation via the regulation of RAS-Racl
by functioning as a ceRNA for miR-101b (40). In patients with NASH, MALAT1 has been found to be highly upregulated compared to normal tissues (41). MALAT1 can aggravate liver fibrosis through the generation of inflammatory chemokines, such as CXCL5 (41). Therefore, MALAT1, through its effects on the inflammatory processes, may modulate liver fibrosis.

Highly upregulated in liver cancer (HULC) plays an important role in liver fibrosis. HULC promotes liver fibrosis and is upregulated in tissues affected by non-alcoholic fatty liver disease (NAFLD) in rat models (42). The inhibition of HULC by siRNA results in the improvement of liver fibrosis and reduces the apoptosis of hepatocytes through the inhibition of the MAP kinase (MAPK) signaling pathway (42).

Small Cajal body specific RNA 10 (SCARNA10) is a lncRNA which is elevated in serum and tissues of patients with liver fibrosis. It has also been shown to be upregulated in liver tissues in a mouse model of liver fibrosis (43). SCARNA10 is a positive regulator of the TGF-β signaling pathway and inhibits polycomb repressive complex 2 (PRC2), which blocks TGF-β signaling (43). TGF-β, TGF-βR1, Smad2, Smad3 and KLF6 levels decline upon SCARNA10 silencing (43).

Liver enriched fibrosis associated lncRNA 1 (LFAR1) is known to promote liver fibrosis. It has been demonstrated that TGF-β-induced hepatocyte apoptosis, CCL4-induced fibrosis and HSC activation are reduced upon lnc-LFAR1 silencing (44). LFAR1 directly binds to the Smad2/3 complex in the cytoplasm, and activates the TGF-β and NOTCH pathways (44). Another lncRNA, SCRG1, is also highly upregulated in fibrotic human liver tissues (45). SCRG1 binds to RNA binding protein tristetraprolin (TTP) and accelerates liver fibrosis (45). The overexpression of TTP leads to the reduction of lncRNA SCRG1 and increases the degradation of matrix metalloproteinase 2 (MMP2) and TNF-α mRNAs, and vice versa (45).

In humans, small nuclear RNA host gene 7 (SNHG7) is significantly upregulated in fibrotic liver tissues (45). The knockdown of SNHG7 prevents HSC activation and collagen overproduction (46). SNHG7 binds to miR-378a-3p. Blocking miR-378a-3p production releases its inhibitory effects on liver fibrosis induced by SNHG silencing. SNHG7 further activates the Wnt/β-catenin pathway to promote liver fibrosis. miR-378a-3p targets disheveled segment polarity 2 (DVL2) protein, which is a component of the SNHG7-mediated Wnt/β-catenin pathway of liver fibrosis (46).

Plasmacytoma variant translocation 1 (PVT1) is a lncRNA which is upregulated in fibrotic liver tissues and activates HSCs (47). PVT1 knockdown reduces type I collagen and α-SMA levels and inhibits HSC activation (47). PVT1 competitively binds to miR-152 and inhibits patched 1 (PTCH1) expression, which in turn activates the Hedgehog pathway, and promotes cell migration and liver fibrosis (47). Activated by transforming growth factor beta (ATB) is a lncRNA which is upregulated in hepatitis C virus (HCV)-mediated liver fibrosis. ATB silencing induces the aberrant expression of miR-200a and reduces β-catenin expression, thereby suppressing HSC activation (48).

lincRNA-p21 is overexpressed during liver fibrosis (49) and promotes liver fibrosis by acting as a downstream effector of the TGF-β signaling pathway by binding to miR-30 (49). In hepatocytes, the knockdown of lincRNA-p21 suppresses CCL4-induced liver fibrosis and inflammation; however, the ectopic expression of miR-30 promotes...
liver fibrosis (49). IncRNA-p21 also binds to miR-17-5p and inhibits the Wnt/β-catenin pathway (50). It can modulate the miR-181b/PTEN cascade (51) and inhibit HSC proliferation through p21 (52). IncRNA-p21 has also been shown to be a potential biomarker of fibrosis in patients with hepatitis B infection (53).

**IncRNAs as inhibitors of liver fibrosis.** There are several IncRNAs which act as suppressors of liver fibrosis; these are usually downregulated in liver fibrosis, and inhibit HSC activation and migration. Conceptually, they can be used as biomarkers. Furthermore, therapeutic strategies involving the overexpression of these RNAs may potentially be a therapeutic approach for liver fibrosis.

Maternally expressed gene 3 (MEG3) is an IncRNA which is significantly downregulated in human liver fibrosis and CCL4-induced fibrosis in experimental models (54). MEG3 prevents fibrosis following TGF-β1-induced LX-2 cell activation. The overexpression of MEG3 in TGF-β1-stimulated LX-2 cells induces p53 activation, cytochrome c release and apoptosis (54). The overexpression of MEG3 also reduces α-SMA and type I collagen levels. Furthermore, as circulating serum MEG3 levels are negatively associated with liver fibrosis in patients with hepatitis, it may further be a useful diagnostic marker (55). Smoothened (SMO) is involved in Hedgehog pathway for EMT; MEG3 binds to SMO and reduces EMT and thereby inhibits HSC activation (56). miR-212 targets MEG3 and acts as a negative regulator of MEG3. Hence, MEG3 possibly regulates EMT and HSC activation through SMO and miR-212. Growth arrested specific transcript 5 (GAS5) is an IncRNA, the expression of which is reduced in fibrotic liver tissues of mice, rats and humans (57). The overexpression of GAS5 inhibits collagen production and HSC activation. GAS5 acts as a ceRNA for miR-222 in the cytoplasm and decreases the levels of p27 tumor suppressor protein, leading to suppressed HSC activation and proliferation (57). GAS5 also acts as a ceRNA for miR-23 in CCL4-induced liver fibrosis and increases miR-23 expression, leading to PTEN inhibition, resulting in the activation of the phosphatidyl-3 phosphate receptor 2 (SIPR2)/sphingosine kinase 2 (SphK2) and regulates the MAP kinase, which dictate the initiation and progression of phospho-extracellular signal regulated kinases 1/2 (p-ERK1/2) (65). Methyl CpG binding protein 2 (MeCp2) is upregulated in liver fibrosis and in activated HSCs. In a rat model of liver fibrosis, the overexpression of MeCp2 has shown to reduce H19 levels and the knockdown of MeCp2 leads to increased levels of H19 (65). The silencing of MeCp2 blocks HSC proliferation. Furthermore, the overexpression of H19 downregulates insulin like growth factor 1 receptor (IGF1R) and vice versa (65). Therefore, MeCp2 possibly targets IGF1R to promote liver fibrosis by negatively regulating H19 and the MeCp2/H19/IGF1R pathway (64,65). H19 is further involved in the regulation of liver fibrosis in the context of cholestasis by modulating cell migration. Epithelial cell adhesion molecule (EpCAM) is negatively regulated by E box binding homeobox 1 (ZEB1) protein. In a mouse model of cholestatic liver fibrosis, H19 was shown to bind to ZEB1 to inhibit EpCAM expression and promote cell migration (66). In patients with biliary atresia (BA)-related liver fibrosis, H19 promotes cholangiocyte proliferation and cholestatic liver fibrosis via the regulation of sphingosine 1 phosphate receptor 2 (SIPR2)/sphingosine kinase 2 (SphK2) and the let-7/high mobility group AT-hook 2 (HMG2A) pathway (67). Cholangiocyte-derived H19-enriched exosomes induce the activation and differentiation of cultured HSCs and HSC-derived fibroblasts (68). Hence, the mechanisms of liver fibrosis involving H19 warrant further thorough investigations in order to develop therapeutic interventions for liver fibrosis modulating such processes. Various IncRNAs, their cellular targets and their roles in liver fibrosis are presented in Table I.

3. **Modulation of signaling pathways by IncRNAs**

As discussed above, IncRNAs are known to interact with and regulate multiple signaling pathways, such as TGF-β, p53, Hedgehog, PI3 kinase/Akt/mTor, Wnt/β-catenin and MAP kinase, which dictate the initiation and progression of liver fibrosis (12,69). The above-mentioned discussions outline some such pathways. The most well-studied pathway for liver fibrosis is the TGF-β signaling pathway, which has been shown to interact with a number of IncRNAs. TGF-β and its downstream effectors, such as Smad proteins control the progression of liver fibrosis, beginning from initial liver injury and inflammation (70-72). The regulation of liver
fibrosis-related pathways by lncRNAs is illustrated in Fig. 2. Some of these pathways promote liver fibrosis, while others suppress it. The mechanisms of action by lncRNAs are usually directed through their complex secondary structures, and the ability to bind to other RNA and protein molecules. This endows them

| IncRNAs               | Cellular target          | Role in liver fibrosis                                                                                   | (Refs.) |
|----------------------|--------------------------|---------------------------------------------------------------------------------------------------------|---------|
| **Activation of liver fibrosis** |                          |                                                                                                         |         |
| NEAT-1               | miR-122, miR-29b         | NEAT-1 promotes liver fibrosis through miR-122/KLF6 and miR-29b/Atg9a pathways                           | (31-34) |
| HOTAIR               | miR-148b, miR-29b        | Acts as ceRNA for miR-148b, miR-29b. HOTAIR regulates miR-148b/DNMT1/MEG3/p53 and miR-29b/PTEN pathways in liver fibrosis | (35,36) |
| HOTTIP               | miR-148a, miR-150        | Acts as ceRNA for miR-148a and miR-150. Activates TGF-β pathway and induces HSC activation              | (37,38) |
| MALAT1               | miR-101b, miR-26b        | Promotes liver fibrosis through miR-26b/SIRT1/Smad3 and miR-101b/Ras-Rac1 and CXCL5 pathways          | (39-41) |
| HULC                 | None                     | Silencing of HULC improves liver pathology in NAFLD rats through inhibition of MAP kinase pathway       | (42)    |
| SCARNA10             | PRC2                     | Regulates TGF-β pathway by inhibiting PRC2                                                            | (43)    |
| Lnc-LFAR1            | Smad2/3                  | Binds to Smad2/3 in cytoplasm to activate TGF-β and NOTCH pathway.                                     | (44)    |
| Linc-SCRG1           | TTP                      | Binds and inhibits TTP and prevents TTP induced degradation of TNF-α and MMP-2.                         | (45)    |
| SNHG7                | miR-378a-3p              | Activates Wnt/β-catenin pathway by negatively regulating miR-378a-3p                                    | (46)    |
| PVT1                 | miR-152                  | Binds as ceRNA to miR-152 which leads to PTCH1 inhibition, resulting in activation of Hedgehog pathway to promote cell migration and liver fibrosis | (47)    |
| Lnc RNA-ATB          | miR-200a                 | ATB knockdown reduced β-catenin expression by upregulating miR-200a expression and suppressed LX-2 cells activation | (48)    |
| LincRNA-p21          | p21, miR-30, miR-181b, miR-17-5p | Promotes liver fibrosis through multiple pathways involving p21, miR-181b/PTEN miR-17-5p/β-catenin and miR-30 | (49-53) |
| **Inhibition of liver fibrosis** |                          |                                                                                                         |         |
| MEG3                 | miR-212, SMO             | Overexpression of MEG3 inhibited HSC activation, induced hepatocyte apoptosis and reduced α-SMA and type I collagen expression | (54-56) |
| GAS5                 | miR-23a, miR-222         | Binds as a ceRNA to miR-23a and miR-222 to inhibit PTEN and increase p27 levels respectively            | (8,57)  |
| Gm5091               | miR-27b, miR-23b, miR-24 | Alleviates alcoholic liver fibrosis by sequestration of miR-23b, miR-27b, miR-24 and down regulation of HSC activation, cell migration, type I collagen expression | (58)    |
| HIF1-AS1             | TET3                     | HIF1-AS1 inhibits LX-2 cell proliferation and is negatively regulated by TET3                          | (59)    |
| ANRIL                | DNMT3A, AMPK             | Overexpression of ANRIL inhibits DNMT3A and AMPK                                                       | (60)    |
| **Dual role in liver fibrosis** |                          |                                                                                                         |         |
| H19                  | MeCP2, IGF1R             | Overexpression of H19 inhibits liver fibrosis by downregulating pERK1/2 and MeCP2/IGF1R pathways     | (64,65) |
|                       | let7, ZEB1               | Promotes cholestatic liver fibrosis by binding to ZEB1 and inhibiting cell migration and activates SIP2/SphK2/let7/HMGA2 pathway | (66-68) |

Table I. IncRNAs in liver fibrosis.

The table lists several IncRNAs and their corresponding cellular targets. Most of these targets are miRNAs and in some cases, signaling proteins. Depending on their role in liver fibrosis, they have been categorized into activators or inhibitors of liver fibrosis. IncRNAs, long non-coding RNAs; miRNAs, microRNAs.
with both unique and diverse traits with which to regulate other molecules (73‑76). There are broadly 2 types of mechanisms through which lncRNAs regulate the activity of the target molecule; firstly, acting as a ceRNA to bind to a miRNA through complementary base pairing and inhibiting the normal function of the miRNA; secondly, by directly binding to a signaling protein through its complex secondary structure and blocking/activating the protein function. An additional mechanism of lncRNA functions includes the binding to DNA to form a triple helical structure. This helical structure can function as a docking site for binding of proteins which can regulate gene expression (77). Recent advances in ncRNA studies have enabled their use as a diagnostic tool (78,79). Circulating ncRNAs from patients with liver fibrosis may be quantified and monitored over the course of time as surrogate markers for disease progression (80). Studies on lncRNA‑based therapy have also been successfully implemented in preclinical models (81). However, clinical trials to verify the efficacy and toxicity of these therapies remain to be performed, at least to the best of our knowledge. Nonetheless, lncRNAs may represent a novel molecular therapeutic approach for liver fibrosis.

4. Regulation of liver fibrosis by other epigenetic mechanisms

The epigenetic control of gene expression is a well-studied area. The present review focuses on DNA methylation, as well as histone methylation and acetylation. DNA methylation is one of the better understood epigenetic mechanisms. The methylation of DNA occurs at the cytosine residue located 5’ to guanosine residue in a stretch of CpG dinucleotides termed CpG islands. The methylation of CpG stretches in the promoter region of a gene and is known to inhibit or repress gene expression. The methylation of cytosine residues prevents the binding of DNA binding proteins required for transcription (82). DNA methylation is carried out by a group of enzymes known as DNA methyltransferases (DNMTs), which are divided into 2 subcategories: Those involved in the de novo methylation of DNA (DNMT3a and DNMT3b) and those involved in maintenance of methylation patterns post-DNA replication (DNMT1) (83‑87).

During the development of liver fibrosis, changes in patterns of DNA methylation, altered activity and the expression of associated enzymes have been observed. These changes are crucial for the establishment and progression of liver fibrosis (88‑90). As previously demonstrated, activated cultured rat HSCs, when treated with the DNA methylation inhibitor, 5-aza, 2-deoxycytidine, have failed to differentiate into myofibroblasts (91). During HSC activation or trans-differentiation, a global DNA hypomethylation is observed (92,93). Although there is an overall demethylation during HSC activation, genome-wide methylation studies have revealed that hypo- or hypermethylation occurring in the promoter region is specific to each gene (92). During HSC activation, the Wnt signaling pathway has been found to be epigenetically
Table II. Epigenetic regulation of genes involved in liver fibrosis.

| Gene      | Gene expression | Epigenetic mechanism involved | (Refs.) |
|-----------|-----------------|-------------------------------|---------|
| Apc2      | Upregulated     | Hypomethylation of gene promoter | (92-95) |
| Wnt5a     | Hypomethylation of gene promoter | (93-95) |
| Actg2     | Hypomethylation of gene promoter | (87) |
| Loxl1     | Hypomethylation of gene promoter | (87) |
| Loxl2     | Hypomethylation of gene promoter | (87) |
| Col4a1/2  | Downregulated   | Hypermethylation of promoter DNA | (95) |
| Col1a1/2  | H3K4 methylation by COMPASS and ASH1 | (100,101) |
| Elastin   | H3K4 methylation by MLL1 | (98) |
| α-SMA     | Transcriptional activation by p300 | (100,101) |
| TGF-β1    | H3K4 methylation by ASH1 HMT | (100,101) |
| TIMP-1    | H3K4 methylation by ASH1 HMT | (100,101) |
| Admats9   | Hypomethylation of promoter DNA | (95) |
| MMP-15    | Hypermethylation of promoter DNA | (95) |
| Smad7     | Hypermethylation of promoter DNA | (96) |
| Pten      | Hypermethylation of promoter DNA | (97) |
| PPAR-γ    | Hypermethylation of promoter DNA by EZH2 at H3K27 and G9a at H3K9 | (105-107,131) |

The table shows the epigenetic regulation of genes involved in liver fibrosis. Hypermethylation or hypomethylation of gene promoters can upregulate or downregulate the gene expression, respectively. Epigenetic enzymes and their targets are shown.

regulated; Apc2 and Wnt5a are upregulated upon promoter hypomethylation (93-95). Similarly, pro-fibrogenic genes, such as Actg2, Loxl1, Loxl2 and Col4a1 are activated upon the hypomethylation of their respective promoters (87). Conversely, DNA hypermethylation causes the transcriptional repression in genes, such as Admats9 and Mmp15 (95), which produce matrix metalloproteinases involved in ECM breakdown and cell migration. Similarly, Smad7, TGF-βR1 antagonist (96) and pro-apoptotic PTEN (97) are also negatively regulated by DNA hypermethylation.

DNMTs are not the only methylating agents in cells. The methylation of histones is another form of epigenetic regulatory mechanism. There are 2 types of histone regulatory enzymes; histone methyl transferases (HMTs) and histone demethyltransferases (HDMTs). Recent studies have indicated the roles of these enzymes in liver fibrosis. The exposure of HSCs to ethanol increases the expression of histone-3 lysine-4 (H3K4) methyl transferase, MLL1, which is recruited the promoter of the pro-fibrogenic elastin gene (98). The TGF-β stimulation of mouse embryonic fibroblasts (MEFs) increases dimethylated (H3K4me2) and trimethylated (H3K4me3) histone levels in the promoters of the pro-fibrogenic genes, Col1a1 and Col1a2. H3K4me2 and H3K4me3 histone signatures are imprinted by a complex protein associated with Set1 (COMPASS). This protein complex COMPASS contains HMTs, such as ASH2 and SET1, which binds to the promoters of pro-fibrogenic genes upon the TGF-β stimulation of HSCs and MEFs (98). ASH1 is also a HMT, which targets H3K4 methylation and is upregulated during HSC transdifferentiation (99). ASH1 binds to the promoters of α-SMA, Col1a1, TIMP-1 and TGF-β1, and causes the transcriptional activation of these genes (100,101).

Enhancer of zeste homologue 2 (EZH2) further acts as a HMT, which is part of polycomb repressor complex 2 (PRC2) that cause H3K27 methylation and promotes the progression of liver fibrosis (102). In CCL4-mediated liver injury, EZH2 expression is increased in activated HSCs (103). The TGF-β stimulation of HSCs can also induce EZH2 (104). The increased expression of EZH2 in activated HSCs causes H3K27 methylation in exons A1 and A2 of peroxisome proliferator activator receptor-γ (PPAR-γ) causing transcriptional repression of PPAR-γ (105,106). The methylation of exons leads to the recruitment of polycomb repressor complex 1 (PRC1) and causes chromatin condensation, thus preventing the transcriptional elongation of downstream exons (107). The downregulation of PPAR-γ is necessary to enable HSC transdifferentiation into myofibroblasts. The epigenetic regulation of genes involved in liver fibrosis through methylation is presented in Table II. Histone acetylation/deacetylation is an important epigenetic mechanism which regulates gene expression and action. Studies have suggested a greater role of HDACs compared to HATs in HSC activation and fibrogenesis. Based on their structure and mechanisms of action, HDACs are grouped into 4 classes: Class I - HDAC1, 2, 3, 8; Class II - HDAC4, 5, 6, 7, 9, 10; Class III - Sirt 1-7; Class IV - HDAC11. During HSC activation, HDAC1 and 2 protein levels have been found to be downregulated (108). In a previous study, in the culture of primary HSCs, HDAC5 and 6 levels peaked at day 4 before decreasing back to baseline levels (109). It was further observed that the pharmacological or siRNA-mediated inhibition of class II HDACs resulted in the upregulation of anti-fibrotic miR-29 (110). The inhibition of HDACs reduced the levels of HSC activation markers e.g., α-SMA, collagen and lysyl oxidase, and also inhibited cell proliferation (109). The inhibition of HDAC1, 2 and 4 by nilotinib has been shown to result in the increased apoptosis and autophagy of activated rat HSCs and human LX-2 cells (110).
Cell death occurs in activated HSCs only, not quiescent ones. MMPs are metalloproteinasises, which play an important role in liver injury and ECM accumulation (111). MMPs are produced by quiescent HSCs, which release growth factors required for wound healing and ECM production (112). However, their levels decrease during HSC transdifferentiation and in liver fibrosis. An interesting link has been found between MMPs and HDACs, which indicates that the ectopic expression of HDAC4 in quiescent HSCs suppresses Mmp9 and Mmp13 gene expression (112). As IncRNAs are regulated in a similar manner as protein-coding genes, a regulatory association of IncRNAs through acetylation is present (113-116). These studies have demonstrated that HDACs play a regulatory role in liver fibrosis and HSC activation, and may be considered as drug targets.

Pharmacological inhibitors of DNMTs, such as 5-aza-2′-deoxycytidine, decitabine, guadecitabine, etc. are being tested for the treatment of hematological cancers and for solid tumors, such as hepatocellular carcinoma (HCC) (117-119). These drugs have been shown to be reasonably effective in safety trials and may have potential for use in the treatment of liver fibrosis. Inhibitors of HDACs are also being used to treat malignancies. These inhibitors block cell proliferation and induce apoptosis, and also suppress HSC activation (120,121). Largazole, an HDAC inhibitor, has been shown to suppress liver fibrogenesis and angiogenesis by inhibiting TGF-β and VEGF signaling (18,122). It has also been shown that sodium valproate, a class I and II HDAC inhibitor, when added to cultured HSCs, blocked TGF-β signaling and downregulated TGF-β induced Col1α1 expression (123). Trichostatin A (TSA), another HDAC inhibitor, has been shown to suppress HSC differentiation into myofibroblasts, and to downregulate α-SMA, and type I and III collagen (124). In CCL4-induced liver fibrosis, TSA has been found to suppress HSC activation through the acetylation of CAAT/enhancer binding protein α (C/EBP-α) (125). These epigenetic inhibitors provide promising therapeutic targets for liver fibrosis.

5. Interplay between histone and DNA methylation in liver fibrosis

The histone code is defined as the epigenetic signature (methylation and/or acetylation) imprinted on histones. The expression of genes is regulated by chromatin remodeling, which in turn is regulated by epigenetic modifications. The interaction between DNA methylation and histone code represents a functional regulatory mechanism which influences chromatin structure (126,127). The epigenetic modifications on DNA provides docking sites for many transcriptional regulatory proteins which determine gene expression.

Methyl CpG binding protein-2 (MeCP2) binds to methylated cytosine residues on stretches of CpG dinucleotides. MeCP2 regulates the expression of the α-SMA gene. MeCP2 knockout mice exhibit a reduced α-SMA expression and collagen deposition in alveolar cells (128,129). Similar effects have been observed in liver fibrosis (103), establishing the role of MeCP2 in myofibroblast differentiation and liver fibrosis. One of the key steps in HSC transdifferentiation is the epigenetic repression of the PPAR-γ gene, which inhibits HSC apoptosis and promotes fibrogenesis. MeCP2 binds to the PPAR-γ promoter and methylates histone H3K9, thereby causing the transcriptional silencing of PPAR-γ (103). MeCP2 also induces the expression of EZH2 histone methyl transferase, which methylates histone H3K27 as a part of PRC2 causing the silencing of PPAR-γ (102). MeCP2 also induces the expression of histone methyl transferase ASH1, which activates the transcription of profibrogenic genes, such as α-SMA, Colla1, TIMP-1 and TGF-β1 during myofibroblast differentiation (103). Hence, a coordinated crosstalk between DNA methylation and the histone code, and the epigenetic enzymes can cause transcriptional activation or repression, depending on the specific molecular interactions near the promoters of target genes. MeCP2 causes the transcriptional repression of genes when it binds to 5-methyl cytosine whereas it activates gene expression when it binds to 5-hydroxymethyl cytosine (130,131). It has been demonstrated that both DNMT1 and H3K9 methyl transferase inhibits PPAR-γ by binding to its promoter during HSC activation (131), whereas the inhibition of DNMT1 and G9a results in PPAR-γ upregulation and the suppression of HSC activation (131).

6. Interactions of IncRNAs with other epigenetic mechanisms

It is of interest to note that the production and/or action of IncRNAs are also regulated by DNA and histone methylation. For example, DNMT1 regulates the IncRNA H19/ERK signaling pathway, which promotes HSC activation and liver fibrogenesis (64). ANRIL is regulated by DNMT3a during HSC activation. DNMT3a suppresses ANRIL expression in activated HSCs with a concomitant increase in the expression of α-SMA, Colla1 and AMPK and p-AMPK in rat and human model of liver fibrosis (60). MeCP2 as discussed above is an epigenetic regulator of pro and anti-fibrogenic genes. However, MeCP2 has also been reported to silence the expression of IncRNA H19 through the IGF1R pathway and to promote HSC proliferation (65). The pro-fibrogenic activity of MeCP2 is regulated by phosphorylation at Serine 80 and its deletion in HSCs results in the altered expression of 284 mRNAs and 244 IncRNAs (132). The understanding of the crosstalk between epigenetic regulators and IncRNAs may help to broaden our understanding of the pathogenesis and subsequent potential therapeutic approaches for liver fibrosis (12,132). EZH2, which is a HMT, methylates H3K27 histone within the exons of PPARγ (102). The methylation of histones leads to the recruitment of the PRC1 complex, which causes the reorganization of the chromatin structure. The binding of PRC1 causes chromatin condensation, which prevents the binding of RNA polymerase II to the DNA template, causing premature termination of transcription (106), indicating that epigenetic mechanisms indirectly regulate gene expression by changing chromatin dynamics.

7. Other considerations

One of the main external stimuli that may affect epigenetic changes is the food that is consumed by an individual. The type of food, as well as the method through which food is prepared, may influence DNA and or histone damage, and subsequent epigenetic alterations, leading to alterations in gene expression. In addition, exposure to environmental...
toxins, such as smoking and other pollutants may also affect cells through epigenetic mechanisms (133). However, the detailed analyses of such an etiology and how the aforesaid changes are influenced, are beyond the scope of the present review. Similarly, as the present review focused on lncRNAs, miRNAs and their effects on liver fibrosis either directly or distally through an exosome-mediated mechanism were not addressed. A previously published review article has addressed this topic (134,135).

8. Conclusions

The present review aimed to highlight the importance of lncRNAs in the initiation and progression of liver fibrosis. The present review also outlined how such processes are regulated by histone and DNA methylation and histone acetylation. The recent impetus into the study of lncRNAs has provided a clearer picture into their roles in HSC activation and liver fibrosis. However, the complex regulatory network of lncRNAs and their associations with a plethora of molecules, renders the elucidation of the underlying mechanisms challenging. A diagrammatic outline is illustrated in Fig. 2. As there may also be disease-specific variation, a therapeutic strategy may involve a combination of disease-specific targets. Furthermore, the majority of the studies have focused on HSCs and the potential contribution by other cells may also have to be investigated in order to obtain a better understanding of the mechanisms involved.

Acknowledgements

Not applicable.

Funding

NG received a fellowship from ICMR no. INDoIFRC/452 I (Y-U) t 201 g2U1HD, Government of India. SC received funding from CHIR grant no. 425360, Government of Canada.

Availability of data and materials

Not applicable.

Authors’ contributions

Both authors (NG and SC) contributed equally to the conception, design, writing, and critical reviewing and reading of the manuscript. Both authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Aydin MM and Akçalı KC: Liver fibrosis. Turk J Gastroenterol 29: 14-21, 2018.
2. Lan T, Li C, Yang G, Sun Y, Zhuang L, Ou Y, Li H, Wang G, Kisseleva T, Brenner D and Guo J: Sphingosine kinase I promotes liver fibrosis by preventing miR-19b-3p-mediated inhibition of CCR2. Hepatology 68: 1070-1086, 2018.
3. Bataller R and Brenner DA:Liver fibrosis. J Clin Invest 115: 209-218, 2005.
4. Karsdal MA, Hjuler ST, Luo Y, Rasmussen DGK, Nielsen MJ, Holm Nielsen S, Leeming DJ, Goodman Z, Arch RH, Patel K and Schuppan D: Assessment of liver fibrosis progression and regression by a serological collagen turnover profile. Am J Physiol Gastrointest Liver Physiol 316: G25-G31, 2019.
5. Chen L, Brenner DA and Kisseleva T: Combating fibrosis: Exosome-based therapies in the regression of liver fibrosis. Hepatol Commun 3: 180-192, 2018.
6. Lledó GM, Carrasco I, Benítez-Gutiérrez LM, Arias A, Royuela A, Requena S, Cuervas-Mons V and de Mendoza C: Regression of liver fibrosis after curing chronic hepatitis C with oral antivirals in patients with and without HIV coinfection. AIDS 32: 2347-2355, 2018.
7. Atta HM: Reversibility and heritability of liver fibrosis: Implications for research and therapy. World J Gastroenterol 21: 5138-5148, 2015.
8. Dong Z, Li S, Wang X, Si L, Ma R, Bao L and Bo A: lncRNA G3ST restraints CCL−1-induced hepatic fibrosis by targeting miR-23a through the PTEN/PI3K/Akt signaling pathway. Am J Physiol Gastrointest Liver Physiol 316: G539-G550, 2019.
9. Dou C, Liu Z, Tu K, Zhang H, Chen C, Yaqoob U, Wang Y, Wen J, van Deursen J, Sicard D, et al: P300 acetylation mediates stiffness-induced activation of hepatic stellate cells into tumor-promoting myofibroblasts. Gastroenterology 154: 2209-2221, 2018.
10. Brandon-Warner E, Benbow JH, Swet JH, Feilen NA, Culberson CR, McKillop JH, delLemos AS, Russo MW and Schrum LW: Adeno-associated virus serotype 2 Vector-mediated reintroduction of microRNA-19b attenuates hepatic fibrosis. Hum Gene Ther 29: 674-686, 2018.
11. Seki E and Schwabe RF: Hepatic inflammation and fibrosis: Functional links and key pathways. Hepatology 61: 1066-1079, 2015.
12. Peng H, Wan LY, Liang JJ, Zhang YQ, Ai WB and Wu JF: The roles of lncRNA in hepatic fibrosis. Cell Biosci 8: 63, 2018.
13. Campana L and Iredale JP: Regression of liver fibrosis. Semin Liver Dis 37: 1-10, 2017.
14. Knolle PA and Wohleber E: Immunological functions of liver sinusoidal endothelial cells. Cell Mol Immunol 13: 347-353, 2016.
15. Heo MJ, Yun J and Kim SG: Role of non-coding RNAs in liver disease progression to hepatocellular carcinoma. Arch Pharm Res 42: 48-62, 2019.
16. Wei L, Wang X, Lv L, Liu J, Xing H, Song Y, Xie M, Lei T, Zhang N and Yang M: The emerging role of microRNAs and long noncoding RNAs in drug resistance of hepatocellular carcinoma. Mol Cancer 18: 147, 2019.
17. Zhou J, Li Y, Liu X, Long Y and Chen J: LncRNA-regulated autophagy and its potential role in drug-induced liver injury. Ann Hepatol 17: 355-363, 2018.
18. Yang Z, Jiang S, Shang J, Jiang Y, Dai Y, Xu B, Yu Y, Liang Z and Yang Y: LncRNA: Shedding light on mechanisms and opportunities in fibrosis and aging. Ageing Res Rev 52: 17-31, 2019.
19. Klinger CM: Non-coding RNAs in breast cancer: Intracellular and intercellular communication. Noncoding RNA 4: 40, 2018.
20. Zoghbi HY and Beaudet AL: Epigenetics and human disease. Cold Spring Harb Perspect Biol 8: a019497, 2016.
21. Sahu B, Pani S, Swalsingh G and Bal NC: Non and epigenetic mechanisms in regulation of adaptive thermogenesis in skeletal muscle. Front Endocrinol (Lausanne) 13: 118, 2019.
22. Martinez SR, Gay MS and Zhang L: Epigenetic mechanisms in heart development and disease. Drug Discov Today 20: 799-811, 2015.
23. Maldonado L and Hoque MO: Epigenomics and ovarian carcinoma. Biomark Med 4: 543-570, 2010.
24. Vrtacnik P, Marc J and Ostaneck B: Epigenetic mechanisms in bone. Clin Chem Lab Med 52: 589-608, 2014.
26. Wu SC and Zhang Y: Active DNA demethylation: Many roads lead to Rome. Nat Rev Mol Cell Biol 11: 607-620, 2010.

27. Barcena-Varela M, Colyn L and Fernandez-Barrena MG: Epigenetic mechanisms in hepatic stellate cell activation during liver fibrosis and carcinogenesis. Int J Mol Sci 20: 2507, 2019.

28. Lachiondo-Ortega S, Mercado-Gómez M, Serrano-Macías M, López-Ortizsoa S, Salas-Villalobos TB, Varela-Rey M, Delgado TC and Martínez-Chantar ML: Ubiquitin-like post-translational modifications in LncRNAs: Small peptides with huge impact in liver fibrosis. Cells 8: 1575, 2019.

29. Dooley S and Ten Dijke P: TGF-β in progression of liver disease. Cell Tissue Res 347: 245-256, 2012.

30. Zhou C, York SR, Chen JY, Pondick JV, Motola DL, Chung RT and Mullten AC: Long noncoding RNAs expressed in human hepatic stellate cells form networks with extracellular matrix proteins. Genome Med 8: 31, 2016.

31. Li QX, Ren ZX, Li K, Huang HJ, Jiang ZZ, Zh TR, Cao HY, Zhang FX and Tan B: Key anti-fibrosis associated long noncoding RNAs identified in human hepatic stellate cell via transcriptome sequencing analysis. Int J Mol Sci 19: 675, 2018.

32. Kong Y, Huang T, Zhang H, Zhang Q, Ren J, Guo X, Fan H and Liu L: The lncRNA NEAT1/miR-29b/Atg9a axis regulates IGFBP3-Pi-induced autophagy and activation of mouse hepatic stellate cells. Cell Physiol Biochem 23: 1169-1185, 2009.

33. Li XQ, ZHU QQ, ZHANG HY, GOU XX, Fan HQ and Liu LX: Interaction between insulin-like growth factor binding protein-related protein 1 and transforming growth factor beta 1 in primary hepatic stellate cells. Hepatobiliary Pancreat Dis Int 16: 395-404, 2017.

34. Yu F, FU WM, ZHU X, WANG WM, Lu YF, Hu BG, Wang H, Liang WC, Fu Y, LI X, FAN HQ and LIU LX: Long non-coding RNA, promotes liver fibrosis and serves as a potential biomarker. Theranostics 9: 3622-3638, 2019.

35. Fu WM, Zhu X, Wang WM, Lu YF, Hu BG, Wang H, Liang WC, Fu Y, Li X, Fan HQ and Liu LX: Long non-coding RNA, promotes liver fibrosis and serves as a potential biomarker. Theranostics 9: 3622-3638, 2019.

36. Yu F, Chen B, Dong P and Zheng J: HOTAIR epigenetically accelerates liver fibrosis by decreasing RNA-binding protein 2 expression. Biochem Pharmacol 144, 2017.

37. Zheng J, Mao Y, Dong P, Huang Z and Yu F: Long non-coding RNA p21 inhibits hepatic stellate cell activation and liver fibrogenesis via p21. FEBS J 282: 4810-4821, 2015.

38. Yu F, Guo Y, Chen B, Dong P and Zheng J: Serum lncRNA p21 as a potential biomarker of liver fibrosis in chronic hepatitis B patients. J Viral Hepat 24: 580-588, 2017.

39. Hu Y, Wu YT, Huang K, Meng XM, Ma TT, Wu BM, Xu FY, Zhang L, Lu WX and Zhu WW: Long non-coding RNA LINC-MEG3 on hepatic stellate cells activation and liver fibrogenesis. Biochem Biophys Acta 1842: 2204-2215, 2014.

40. Chen MJ, Wang XG, Sun ZX and Liu XC: Diagnostic value of lncRNA-MEG3 as a serum biomarker in patients with hepatitis B complicated with liver fibrosis. Eur Rev Med Pharmacol Sci 23: 4360-4367, 2019.

41. Yu F, Geng W, Dong P, Huang Z and Zheng J: LncRNA-MEG3 inhibits activation of hepatic stellate cells through SMO protein and miR-212. Cell Death Dis 9: 1014, 2018.

42. Yu F, Zheng J, Mao Y, Dong P, Lu Z, Li G, Cui L and Fan Z: Long non-coding RNA p21 regulates the Wnt/β-catenin pathway by sponging microRNA-17-5p. Cell Physiol Biochem 41: 1970-1980, 2017.

43. Liu R, Li X, Zhu W, Wang Y, Zhao D, Wang X, Gurley EC, Yang H, Lai G, Zhang L and Yang J: Cholangiocyte-derived exosomal long non-coding RNA H19 promotes hepatic stellate cell activation and cholestatic liver fibrosis. Hepatol Int 10: 1317-1339, 2016.

44. Liu R, Li X, Zhu W, Wang Y, Zhao D, Wang X, Gurley EC, Yang H, Lai G, Zhang L and Yang J: Cholangiocyte-derived exosomal long non-coding RNA H19 promotes hepatic stellate cell activation and cholestatic liver fibrosis. Hepatol Int 10: 1317-1339, 2016.

45. Fu N, Zhao SX, Kong LB, Du JH, Ren WG, Han F, Zhang QS, Li WC, Cui P, Wang RQ, et al: LncRNA-ATB/microRNA-200a/β-catenin regulatory axis involved in the progression of HCV-related hepatic fibrosis. Gene 618: 1-7, 2017.

46. Yu X, Zhang Y, Zheng X, Deng J, Li H, Kang Z, Cao Z, Huang Z, Ding D, Dong L, et al: H19 and LncRNA-ATB/microRNA-200a/β-catenin regulatory axis involved in the progression of HCV-related hepatic fibrosis. Gene 618: 1-7, 2017.
72. Caja L, Dituri F, Mancarella S, Caballero-Diaz D, Moustakas A, Giannelli G and Fabregat I: TGF-β and the tissue microenvironment: Relevance in fibrosis and cancer. Int J Mol Sci 19: 1294, 2018.

73. Martens L, Rühle F and Stoll M: LncRNA secondary structure in the cardiovascular system. Noncoding RNA Res 2: 137-142, 2017.

74. Zampetaki A, Albrecht A and Steinhofel K: Long non-coding RNA structure and function: Is there a link? Front Physiol 9: 1201, 2018.

75. He Z, Yang D, Fan X, Zhang M, Li Y, Gu X and Yang M: The roles and mechanisms of IncRNAs in liver fibrosis. J Intern Med 21: 1482, 2020.

76. Kuo CC, Hänzelmann S, Sentürk Cetin N, Frank S, Sajbouz B, Derks JP, Akhade VS, Ahuja G, Kanduri C, Grummt I, Mannaerts I, Eysackers N, Onyema OO, Van Beneden K, Albrecht A and Etzioni A: Detection of RNA-DNA binding sites in long noncoding RNAs. Nucleic Acids Res 47: e32, 2019.

77. Teng KY and Ghoshal K: Role of noncoding RNAs as biomarker and therapeutic targets for liver fibrosis. Gene Expr 16: 155-162, 2015.

78. Roderbusch C, Mollnow T, Bongaerts B, Elfimova N, Vargass Cardenas D, Berger K, Zimmermann H, Koch A, Vucur M, Luedde M, et al: Micro-RNA profiling in human serum reveals compartment-specific roles of miR-571 and miR-652 in liver cirrhosis. PLoS One 7: e23999, 2012.

79. Klose RJ and Bird AP: Genomic DNA methylation: The mark and its mediators. Trends Biochem Sci 31: 89-97, 2006.

80. Jiang F, Parsons CJ and Stefanovic B: Gene expression profile of activated hepatic stellate cells via inhibition of histone deacetylases 4: Implication in tissue fibrosis. Am J Pathol 177: 1915-1928, 2010.

81. Gujar H, Weisenberger DJ and Liang G: The roles and mechanisms of lncRNAs in liver fibrosis. J Hepatol 57: 705-714, 2012.

82. Okano M, Bell DW, Haber DA and Patel DJ: DNA methylation by DNA methyltransferases. Epigenetics 4: 141-158, 2009.

83. Bian EB, Huang C, Wang H, Chen XX, Zhang L, Lv XW and Li J: Repression of Smad7 mediated by DNMT1 determines hepatic stellate cell activation and liver fibrosis in rats. Toxicol Lett 224: 175-185, 2014.

84. Panbieniaco C, Oben JA, Vinciguerra M and Piazzon V: Senescence in hepatic stellate cells as a mechanism of liver fibrosis reversal: A putative synergy between retinoic acid and PARP-gamma signalings. Clin Exp Med 17: 269-280, 2017.

85. Panbieniaco C, Oben JA, Vinciguerra M and Piazzon V: Senescence in hepatic stellate cells as a mechanism of liver fibrosis reversal: A putative synergy between retinoic acid and PARP-gamma signalings. Clin Exp Med 17: 269-280, 2017.

86. Shaker ME, Ghani A, Shiha GE, Ibrahim TM and Mehal WZ: Matrix metalloproteinases in liver injury, repair and fibrosis. Matrix Biol 35-36, 2015.
113. Ding G, Li W, Liu J, Zeng Y, Mao C, Kang Y and Shang J: LncRNA GHET1 activated by H3K27 acetylation promotes cell tumorigenesis through regulating ATF1 in hepatocellular carcinoma. Biomed Pharmacother 94: 326-331, 2017.

114. Yang F, Hao XS, Yuan SX, Zhang L, Zhou WP, Wang F and Sun SH: Repression of the long noncoding RNA-LET by histone deacetylase 3 contributes to hypoxia-mediated metastasis. Mol Cell 49: 1083-1096, 2013.

115. Pope C, Mishra S, Russell J, Zhou Q and Zhong XB: Targeting H19, an imprinted long non-coding RNA, in hepatic functions and liver diseases. Diseases 5: 11, 2017.

116. Zhu XT, Yuan JH, Zhu TT, Li YY and Cheng XY: Long noncoding RNA glypican 3 (GPC3) antisense transcript 1 promotes hepatocellular carcinoma progression via epigenetically activating GPC3. FEBS J 283: 3739-3754, 2016.

117. Issa JJ, Roboz G, Rizzieri D, Jabbour E, Stock W, O’Connell C, Yee K, Tibes R, Griffiths EA, Walsh K, et al: Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: A multicentre, randomised, dose-escalation phase 1 study. Lancet Oncol 16: 1099-1110, 2015.

118. Jansen YJL, Verset G, Schats K, Van Dam PJ, Seremet T, Zhuang M, Fang WH, Zhao J, et al: Transforming growth factor-β and vascular endothelial growth factor signalling. Liver Int 33: 504-515, 2013.

119. Kuang Y, El-Khoueiry A, Taverna P, Ljungman M and Neamati N: Chromatin plasticity: A versatile landscape that underlies cell fate and identity. Science 361: 1332-1336, 2018.

120. Hu B, Gharae-Kermani M, Wu Z and Phan SH: Essential role of MeCP2 in the regulation of myofibroblast differentiation during pulmonary fibrosis. Am J Pathol 178: 1500-1508, 2011.

121. Park KC, Park JH, Jeon JY, Kim SY, Kim JM, Lim CY, Lee TH, Kim HK, Lee HG, Kim SM, et al: A new histone deacetylase inhibitor improves liver fibrosis in BDL rats through suppression of hepatic stellate cells. Br J Pharmacol 171: 4820-4830, 2014.

122. Liu Y, Wang Z, Wang J, Lam W, Kwong S, Li F, Friedman SL, Zhou S, Ren Q, Xu Z, et al: Sodium valproate blocks the transforming growth factor (TGF)-β1 autocrine loop and attenuates the TGF-β1-induced collagen synthesis in a human hepatic stellate cell line. Int J Mol Med 28: 919-925, 2011.

123. Takamura H, Hironori H, Nakagawara H, Ohnishi I, Takamura H, Ninomiya I, Kitagawa H, Fushida S, Tani T, et al: Sodium valproate blocks the transforming growth factor (TGF)-β1 autocrine loop and attenuates the TGF-β1-induced collagen synthesis in a human hepatic stellate cell line. Int J Mol Med 28: 919-925, 2011.

124. Niki T, Rombouts K, De Bleser P, De Smet K, Rogiers V, Schuppan D, Yoshida M, Gabbianni G and Geerts A: A histone deacetylase inhibitor, trichostatin A, suppresses myofibroblastic differentiation of rat hepatic stellate cells in primary culture. Hepatology 29: 858-867, 1999.

125. Ding D, Chen LL, Zhai YZ, Hou CJ, Tiao LL, Lu SH, Wu J and Liu XP: Trichostatin A inhibits the activation of Hepatic stellate cells by increasing C/EBP-α Acetylation in vivo and in vitro. Sci Rep 8: 4395, 2018.

126. Wang H, Wang F and Li J: The role of methyl-CpG binding protein 2 in liver fibrosis. Toxicology 309: 9-14, 2013.

127. Smith E and Shilatifard A: The chromatin signaling pathway: Diverse mechanisms of recruitment of histone-modifying enzymes and varied biological outcomes. Mol Cell 40: 689-701, 2010.

128. Yang JJ, Tao H, Deng ZY, Lu C and Li J: Non-coding RNA-mediated epigenetic regulation of liver fibrosis. FEBS J 277: 2015-2021, 2010.